Nexalis Therapeutics Limited has released a press release.
Binding Letter of Intent to replace existing $53m facility
Earlier from Nexalis Therapeutics
- Suspension from Quotation
- Mar26 Appendix 4C Cash Flow Report
- Significant Milestone - First Patient Screened IRX-211 Ph2
- First patient dosed in IRX-616a Phase 1 trial